Phase 1
Ended Awarded Last action
- Contract number
- 75N93021F00202
- Awardee
-
Dynport Vaccine Company LLC UEI LXNEGTYDR755
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,120,677
Award facts
- Contract value 100% obligated
- $4,120,677.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $31,982 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $284,064 | |
| Supplemental Agreement for work within scope | $133,451 | |
| Supplemental Agreement for work within scope | $105,440 | |
| Supplemental Agreement for work within scope | $648,341 | |
| Supplemental Agreement for work within scope | $43,725 | |
| Supplemental Agreement for work within scope | $175,697 | |
| Supplemental Agreement for work within scope | $22,770 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $1,877,973 | |
| Original award | $797,234 |
Show all 12
About this award
This delivery order, awarded on May 13, 2021, to Dynport Vaccine Company LLC (a General Dynamics subsidiary) by the National Institute of Allergy and Infectious Diseases (NIAID), provides $4.12 million under a cost-plus-fixed-fee structure to establish a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The work is being performed in Frederick, Maryland, with an ultimate completion date of January 31, 2025. This delivery order is issued under the $346 million Early Phase Clinical Trial Units Indefinite Delivery, Indefinite Quantity (IDIQ) contract, which funds Phase 1 trial services across multiple awardees. No set-aside designation was applied to this award, meaning it was competed through full and open competition.
Dynport brings substantial experience in infectious disease research and development to this engagement, with a documented history of providing preclinical development, clinical trials, diagnostic testing, vaccine stability evaluations, and current Good Manufacturing Practice (cGMP) production services. The company also holds the $30 million Preclinical Services for Biopharmaceutical Product Development IDIQ from NIAID, which supports vaccine and therapeutic candidates from early development through preclinical advancement. Two subcontractors support this effort: Iqvia Government Solutions Inc., a healthcare data and clinical research services provider (awarded August 28, 2024), and Kcas LLC (awarded June 5, 2023).
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Iqvia Government Solutions Inc. | $181,898 |
Quick answers
Who was awarded contract 75N93021F00202?
75N93021F00202 was awarded to Dynport Vaccine Company LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 13, 2021.
How much is contract 75N93021F00202 worth?
The government has obligated $4,120,677 on 75N93021F00202.
Is contract 75N93021F00202 an order under another contract?
Yes. 75N93021F00202 is a delivery order under HHSN272201500005I, an indefinite delivery contract, on Therapeutics Against Infectious Diseases Phase 1.
Was contract 75N93021F00202 competed?
The extent of competition for 75N93021F00202 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award